Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inamed Finalizing Lap-Band Treatment IDE Plans, Collecting Three-Year Data

This article was originally published in The Gray Sheet

Executive Summary

Inamed is expecting to hear from FDA within the next few weeks about expanding its Lap-Band obesity treatment training program under a treatment investigational device exemption, President and co-CEO Ilan Reich told a July 25 teleconference announcing second-quarter financial results.
Advertisement

Related Content

Inamed
Inamed
Inamed's Two-Year Data Insufficient For Lap-Band Approval - Panel
Inamed's Two-Year Data Insufficient For Lap-Band Approval - Panel
Advertisement
UsernamePublicRestriction

Register

MT013667

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel